

# Radiobiological Aspects in Determination of Residual Normal Tissue Tolerance Doses for Various Re-irradiation Scenarios

Pavol Matula\*, Jan Koncik, Martin Jasencak

East Slovak Institute of Oncology, Kosice, Slovakia

**Email address:**

[doc.p.matula@gmail.com](mailto:doc.p.matula@gmail.com) (P. Matula)

\*Corresponding author

**To cite this article:**

Pavol Matula, Jan Koncik, Martin Jasencak. Radiobiological Aspects in Determination of Residual Normal Tissue Tolerance Doses for Various Re-irradiation Scenarios. *Cancer Research Journal*. Vol. 9, No. 4, 2021, pp. 202-208. doi: 10.11648/j.crj.20210904.14

**Received:** October 31, 2021; **Accepted:** November 19, 2021; **Published:** December 29, 2021

---

**Abstract:** *Introduction.* The current state of re-irradiation in radiation oncology is characterized by the high heterogeneity of re-irradiation practices between institutions. The implementation of imaging methods and new irradiation techniques has created scope for the development and application of more accurate re-irradiation procedures associated with the use of radiobiological modelling, that are allowing often the replacement of palliative intent by radical. Therefore, the preparation of a planning protocol for re-irradiation is a significantly more complex process than for primary treatment planning. It requires quantified dose-volume records from primary and second series, radiobiological knowledge of the regeneration capacity of organs at risk (OaR) and using an appropriate SW-tool for modelling tumour control probability (TCP) versus normal tissue complication probability (NTCP) from individual DVH and pause between series taking into account significant differences in OaR regeneration capacity. Significant restoration takes place within 3-6 months e.g. in the skin, spinal, cord, brain, brain stem and lungs. Other tissues, e.g. kidneys, heart, bladder, have only a small regenerative capacity. This knowledge should be included in the process of preparing a re-irradiation protocol for an individual patient. *Purpose:* In this contribution we present - an overview of residual tolerance doses for selected OaR in the measure % EQD2<sub>cum</sub> (biologically equivalent dose of 2 Gy in percents) for 15 - the most critical OaR extirped from retrospective studies (e.g. %EQD2<sub>cum</sub> for brain stem, spin cord and bladder are 170%, 140%, 125%, respectively). *Material and methods:* A description of simultaneous determination of residual doses in re-irradiation with an original OaR regeneration model (REG<sub>pause</sub>) by the authors of paper included into the calculation of the normal tissue complication probability (NTCP) for individual irradiation scenarios of re-irradiation using the "BioGray" program developed in the workplace of authors. *Results:* A demonstration of the benefits of the tumour control probability (TCP) versus NTCP prediction depending on the location and volume of the clinical tumour volume (CTV) in the primary and second series. *Conclusion:* The use of the methodology of radiobiological modelling brings a shift from paradigm of verbalism and estimations in the management of re-irradiation to quantitative evaluation of these processes and utilization of translation research knowledge linked to the current technological possibilities of application IMRT, VMAT, SRS/SBRT and proton therapy.

**Keywords:** Re-irradiation, Cumulative EQD2, REG<sub>pause</sub>, NTCP, SW BioGray

---

## 1. Introduction

The issue of re-irradiation cases of relapse of cancer or infield of secondary malignancies is a significantly more demanding decision-making process in assessing its benefit versus risk to the patient compared to the process of initial radiotherapy. While retrospective studies provide an estimate

of the tolerable cumulative doses per OaR [1, 2, 4-6, 11, 12, 15, 18] they do not provide algorithms and methods for determination of the residual tolerance doses in complex individual clinical scenarios of re-irradiation.

The expert panels in the works [7, 12] after targeted multi-institutional surveys of the management of re-irradiation procedures in both H&N and extra-cranial tumors concluded

that the status quo is characterized by:

1. high heterogeneity of re-irradiation practices between institutions!
2. Insufficient data from retrospective studies.
3. Critical selection of patients for re-irradiation.

Expert groups from the above reviews recommended compliance with the following conditions for the indication of re-irradiation:

1. Contra-indications to surgery.
2. Vorable localization of relapse or secondary tumors.
3. Re-irradiation with a curative intent requires EQD2  $\geq 60$ Gy should be.
4. Associated with chemotherapy (including biological therapy).
5. Realistic options for minimizing the dose in OaR.
6. Sufficient interval from initial RT  $\geq 6$  months.
7. A well-defined volume of relapse or secondary tumor (CTV).
8. Use of more advanced therapeutic technologies and hypo-fraction modes (IMRT, VMAT, SRS, FSRT, proton therapy).

In the context with these recommendations, setting an acceptable plan for the second series with a palliative or curative intent is actually the solution of the multi-parameter NTCP function with parameters:

$$NTCP = F(BED_1, DVH_1, REG_{\text{pause}}, BED_2, DVH_2) \quad (1)$$

where

$DVH_1$  and  $DVH_2$  - available from treatment planning systems (TPS);

$BED_1$  and  $BED_2$  - biological effective doses in series 1 and 2;

$REG_{\text{pause}}$  is the OaR regeneration model described below.

Addressing this complex task requires a quantifiable inclusion and simultaneous assessment of these parameters not only from TPS, but also the use of appropriate software for radiobiological modeling BED / EQD2 and biostatistic measures TCP/NTCP. For calculation of mentioned measures in our program BioGray we use the models described at the work [9]. Unfortunately, such a tool is not standard equipment for radiotherapeutic centres at present.

## 2. Purpose

The purpose of the contribution is to provide:

1. A tabular overview of residual tolerance doses in EQD<sub>2</sub> for selected OaR determined from retrospective re-irradiation studies.
2. A description of analytical model  $REG_{\text{pause}}$  for calculation of residual tolerance dose to OaR.
3. A demonstration of the benefits of TCP/NTCP simulation depending on the location and volume of CTV in the primary and second series.

## 3. Material and Methods

From retrospective studies [1, 2, 4-6, 11, 12, 15] it was

found that late-response tissue and organ regeneration (OaR) allows the application of the second series up to 50-80% of BED in relation to initial series. This means that if the organ tolerance level in the first series has already reached the accepted tolerance threshold, in the second series OaR may tolerate a cumulative dose of BED at 150-180% initial. In a situation where the organ in the first series was irradiated only at the level of e.g. 50% of its tolerance the dose in the second series may be applied substantially higher (by the calculated difference in the level of tolerance not achieved). The volume dependence of OaR tolerance in re-irradiation, the interval between initial radiotherapy and re-irradiation also play a very important role. OaR regeneration is predominantly saturated within 2 years. [2, 9]

In order to estimate or determine the residual tolerance of OaR, author at the work [18] proposed the concept of so-called "cumulative percentage dose" (hereinafter  $\%BED_{\text{cum}}$ ), which can be expressed by:

$$\%BED_{\text{cum}} = \%BED_{1.\text{series}} + \%BED_{\text{retr.}} \quad (2)$$

Relationship  $\%BED_{\text{retr.}}$  versus  $\%BED_{1.\text{series}}$  for four selected tissues (skin, lung, spinal cord, kidney) is demonstrated in the figure 1.




Figure 1. Demonstration of the  $\%BED_{\text{retr.}}$  vs.  $\%BED_{1.\text{series}}$  for some tissues.

**Interpretation:** Coordinate X determines the initial dose size as a percentage of the tolerance dose for the monitored OaR, the Y-coordinate determines the applied dose as a percentage of initial series, the intermittent line represents the level of tolerance in hypothetical - zero tissue regeneration. The points above the dashed line represent the successful results of the re-irradiation, the points below the dashed line represent the results of insufficient regeneration capacity of the organ (e.g. kidney - source: Stewart 2006) (18).

The radiobiological quantity of BED is more often expressed at the value of the NTD (a normalized total dose) or EQD2 (a biologically equivalent dose of 2 Gy per fraction) defined by the relationship:

$$NTD = EQD_2 = \frac{BED}{RE} = N_{new} \cdot d_{new} \cdot \frac{(d_{new} + \alpha / \beta)}{(2 + \alpha / \beta)} \quad (3)$$

where RE expresses the relative efficiency of the new fractionation in the form:

$$RE = (1 + d_{new}/(\alpha/\beta))$$

$N_{new}$  = selected new number of fractions  $d_{new}$  = selected

new dose/fraction  $\alpha/\beta$  = coefficient of radiosensitivity.

For late reacting tissues is a generally accepted value  $\alpha/\beta$  = 3Gy except for the spinal cord where  $\alpha/\beta$  = 2 Gy.

From a retrospective study [11] on brain re-irradiation in 3 therapeutic modalities - conformal external therapy (CRT), stereotactic surgery (SRS) and fractionated stereo radiotherapy (FSRT), data were obtained on the amount of the tolerated cumulative dose expressed in EQD<sub>2</sub> that did not lead to brain radio-necrosis. The results are summarized in the table 1.

**Table 1.** Results of retrospective analysis – tolerance of brain during re-irradiation.

Type of modality	Accepted EQD2 (brain)	Cumulative EQD2 (brain)	Cumulative EQD2 in% initial dose
CRT	60 Gy	< 80 - 100 Gy	< 133 – 170%
SRS	60 Gy	< 90 - 140 Gy	< 150 – 233%
FSRT	60 Gy	< 112 -137 Gy	< 186 – 228%

The above retrospective analysis provided two other significant conclusions:

1. There is no correlation in the occurrence of radionecrosis and the length of the interval between initial radiotherapy and the second series.
2. There is a statistically significant correlation between the occurrence of radionecrosis and irradiated brain volume (p=0.016).

The following conclusions were drawn at the work [17]

devoted to retrospective analysis of re-irradiation of spinal cord:

1. Permissible EQD<sub>2(cum)</sub> <=60 Gy (% EQD<sub>2(cum)</sub> <= 140%).
2. No significant correlation of radiation myelitis has been established at an interval greater than 1 year.

At the work [4] the acceptable cumulative doses for additional OaR were described. Those database been converted (for consistency with data in the table 1.) to the EQD<sub>2</sub>. The table 2 contains data for OaR in H&N region, the table 3 for OaR in extra-cranial area.

**Table 2.** Cumulative and residual tolerance doses in EQD2 for H&N region.

Organ at Risk	InitialEQD2 (Gy)	Cumulative EQD2 (Gy)	Cumulative EQD (in%)	Acceptable residual EQD2 (for pause = 1 year)
Brain **	60	100	170	<=40
Brain stem**	54	80	150	<=36
Spinal cord ***	44	60	140	<=17
Opt. nerve / chiasma***	50	66	150	<=8
Retina***	45	63	140	<=18
Eye lens ***	9	12	130	<= 3
H&N soft tissues **	60	96	160	<=36
Parotid***	32	45	150	<=13
Mandible (TMJ)**	60	84	160	<=24

Legend: \*= partial volume 1/3, \*\*=partial volume 2/3, \*\*\* whole volume.

**Table 3.** Cumulative and residual tolerance doses in EQD2 for OaR in extracranial area.

Organ at Risk	Initial EQD2 (Gy)	Cumulative EQD2 (Gy)	Cumulative EQD2 (in%)	Accepted residual EQD2 (Gy) (pause >= 1 year)
Heart *	60	80	133	<=20
Great vessels **	60	100	160	<=40
Lung **	35	56	160	<=21
Esophagus	55	74	135	<= 9
Rectum***	60	96	160	<=36
Bladder ***	65	72	110	<= 7
Femoral Head***	52	71	140	<=18

Legend: \* partial volume 1/3, \*\*partial volume 2/3, \*\*\* whole volume.

It should be noted and stressed that the estimation of tolerance residual doses in the last column of the tables 2 and 3 represent only the first gross approximation related to the following conditions:

1. The initial RT series were administered at the limits of the OaR tolerance dose (column 2).
2. It is set to pause between series >=1 year.

3. It does not include variability of OaR tolerance depending on irradiated OaR volume.

4. The limits of residual tolerance doses of OaR are considered to be identical with partial volume quoted in the first column of the table.

From the above it follows that residual tolerance doses may be significantly higher at the lower dose-volume load of

OaR in the initial series, but also in the re-irradiation series. These dependencies can be comprehensively addressed only using a suitable software involving real data from DVH, EQD2 calculations and a real pause between series.

Using extirped data from retrospective studies summarized in the tables 2 and 3 on acceptable cumulative%EQD2, we attempted to develop an analytical model that could allow the calculation of the residual tolerance dose and simulate NTCP prediction in the clinical scenarios.

#### Regeneration Model $REG_{pause}$

Recovery at OaR with a late response begins after 7-8 weeks from the start of radiotherapy and ends mostly after 2 years. However, this process of tissue regeneration is not linear. Therefore, the authors of the paper proposed an


analytical model that replaces the linear regeneration approximation with a sigmoidal curve expressed by the Poisson function in the form of:

$$F(x) = \sum_{i=1}^x \frac{\exp(-d_{inf}) / d_{inf}^i}{i!} \quad (4)$$

where

$x$  = number of days on pause between initial and second series  $d_{inf}$  = dose in inflexion point on sigmoidal curve (in Gy)

The application of the model  $REG_{pause}$  is presented in the Figure 2 for spinal cord.



**Figure 2.** Graphical presentation of the model  $REG_{pause}$  for determination of residual tolerance dose in re-irradiation of the spinal cord.

By fitting the model constant at the inflection point ( $d_{inf} = \lambda = 9.4$  Gy) from experimental data [17]. The residual tolerance dose can be determined for any time interval between the first series and the re-irradiation.

Example: When we are applying full spinal cord tolerance EQD2 = 47 Gy in the initial series for re-irradiation after 6, 12, 18 months the residual tolerance dose reaches: 7.8 Gy, 17.5 Gy and 18.8 Gy, respectively. The residual tolerance dose at greater pause is no longer increased.

The parameters of Poisson's function  $F(x)$  for residual tolerance doses of other OaR listed in table 2 and 3 have been obtained using the same procedure as shown for the spinal cord in the figure 2. These data will be gradually refined from new clinical data from retrospective studies. The  $REG_{pause}$  calculation algorithm is implemented in the SW BioGray and in an interactive dialogue (by changing the number of fractions or dose pre fraction) the different

scenarios can be simulated for an optimal re-irradiation plan.

## 4. Results

The use of the proposed  $REG_{pause}$  model for determination of residual tolerance dose in re-irradiation is demonstrated in the example of re-irradiation of a patient with Ca laryngis. The patient received primary treatment with TD = 70 Gy in 35 fr./2 Gy. (25 fr./2 Gy + boost 10 fr./2 Gy). After 23 months, there was an indication of secondary malignancies with CTV localisation displaced cranially by 3.5 cm. The re-irradiation plan consisted of the radiotherapy with the curative intent of TD = 70 Gy in 35 fr./2 Gy. The Figure 3. shows isodose plans with CTV applied in the first series in 2015 and the second series in 2017.






Figure 3. Lateral isodose plans from the initial series in 2015 and re-irradiation in 2017.

It is clear from the pictures that the CTV of secondary malignancies is shifted cranially by 3,5 cm, in which the treatment plan already causes a minimal load on the spinal cord during re-irradiation. From DVH<sub>1</sub> statistics of the initial series we received  $D_{\max(\text{spin.cord})} = 47$  Gy. From DVH<sub>2</sub>

statistics of the treatment plan in second series – 35fr./ 2Gy we receive  $D_{\max(\text{spin.cord})} = 9$  Gy.

The output of TCP/NTCP from SW BioGray for real scenario – different CTV is shown in the figure 4. Applications of the SW BioGray are described at the works [8-10].




Figure 4. Outputs of TCP/NTCP for real scenario – different CTV in initial and second series (SW BioGray).  $NTCP_{\text{spin.cord}} = 0\%$  (red curve).

Note 1: In the figure 4. is also displayed an NTCP curve that responds to a hypothetical situation - if the spinal cord would have no regenerative capacity ! In this case, the NTCP prediction would be  $\approx 30\%$ . (green curve).

In the figure 5 is shown the output of the TCP/NTCP for a hypothetical scenario – when CTV matches in series 1. and 2. which would result in a high dose load on the spinal cord and thus exceed its tolerance (EQD2 = 66Gy; NTCP= 33.2%)!




Figure 5. Output of TCP /NTCP for a hypothetical scenario - (CTV are the same in both series),  $NTCP_{spin.cord} = 28\%$  (red curve).

Note 2: In the figure 5 is also displayed a hypothetical situation - when the spinal cord would be without regeneration capacity. Then NTCP would be = 93% ! (green curve).

**Comment and summary:** The outputs TCP/NTCP allocate on crucial significance of CTV locations in initial and second series. When the position of the new CTV is markedly different the residual tolerance dose of OaR can be sufficiently higher for the second series which made it possible to apply re-irradiation with the curative intent. In not the case there exists a risk of overrun of tolerance.

## 5. Discussion

Current data from the knowledge base on re-irradiation is still insufficient. There is a lack of works with a more detail description of re-irradiation management including available radiobiological knowledge. International recommendations do not include base knowledge data from observed outputs of accepted cumulative EQD2. The first quatitative outputs in the measures EQD2 offer the works [5, 6, 10, 11, 17, 19]. Our contribution is an attempt quantitatively to assess the complex relationships in the re-irradiation process-using dose - volume statistics and the use of mathematical models to describe the OaR regeneration processes and their implementation in the NTCP calculation.

The use of the methodology of radiobiological modeling could bring a shift from paradigm of verbalism in the

management of re-irradiation to quantitative evaluation of these processes and utilization of knowledge from translational research linked to the current technological possibilities of application of re-irradiation by techniques IMRT, VMAT, SRS/SFRT and proton therapy.

## 6. Conclusion

The quantification of residual tolerance doses to OaR from retrospective studies and the implementation of the proposed  $REG_{pause}$  model describing the time dependence of OaR regeneration after initial radiotherapy and the use of dose-volume histograms (DVH) from TPS opens up possibilities for more detailed radiological analysis in the measure EQD2 and biostatistical measures TCP/NTCP with the simulation of various scenarios in the decision-making process in re-irradiation.

The model  $REG_{pause}$  and computing procedure is currently embedded in the SW BioGray developed by authors and that option has become available to its users. The need for further targeted research in the management of re-irradiation using the tools currently provided by the "queen of sciences" - mathematics in various fields of medicine, including radiation oncology.

## Competing Interest

The authors declare that they have no competing interests.

## References

- [1] Caudell J. et al.: Volume, Dose, and Fractionation Considerations for IMRT-based Reirradiation in Head and Neck Cancer: A Multi-institution Analysis Int J Radiat Oncol Biol Phys. 2018 Mar 1; 100 (3): 606-617.
- [2] Crevoisier R. D. et al.: Full dose reirradiation combined with chemotherapy after salvage surgery in head and neck carcinoma Cancer 2001 Jun 1; 91 (11): 2071-6.
- [3] Dale R. G., Jones B.: Radiobiological modelling in Radiation Oncology, BIR 2007.
- [4] Das S. et al.: Recovery and Tolerance of the Organs at Risk during Rerradiation J. Curr. Oncol. 2018, Vol.1,1, pp. 23-28.
- [5] Embring A. et al.: Overlapping volumes in re-irradiation for head and neck cancer – an important factor for patient selection Radiation Oncology, vol. 15. Nr 147, 2020.
- [6] Embring A. et al.: Re-Irradiation for Head and Neck Cancer: Cumulative Dose to Organs at Risk and Late Side Effects, Cancers ~~cancers~~ 2021 Jun 25; 13 (13): 3173.
- [7] Krause A. et al.: Recommendation of experts Radiation Oncology 2017, 12, 194.
- [8] Matula P.: Contribution of Simultaneous Modelling Radiobiological Effects in Radiation Oncology, Habilitation work Universititis Trnaviensis, 2009.
- [9] Matula P., Koncik J.: Key to Radiobiological Modelling Effects in radiation Oncology, Lambert Academic Publishing, 2018, ISBN 978-613-7-34224-4.
- [10] Matula P., Koncik J., Jasenčák M., Dubinsky P.: Radiobiological aspects of re-irradiation and their modelling in the determination of the tolerance dose in organs at risk; Klin Onkol 2020; 33 (Suppl 1): 1– 7.
- [11] Mayer R., Sminia P.: Reirradiation tolerance of the human brain. Int J. Radiat Oncol Biol Phys 2008; 70: 1350-60.
- [12] McDonald Mark W. et al.: ACR Appropriateness Criteria® Retreatment of Recurrent Head and Neck Cancer After Prior Definitive Radiation: Expert Panel on Radiation Oncology–Head and Neck Cancer, IJROBP Vol. 80, Issue 5, 2011, pages 1292-1298.
- [13] Mi-Sook Kim et al.: Radiobiological mechanisms of stereotactic body radiation therapy and stereotactic radiation surgery, Radiation Oncology Journal 2015; 33 (4): 265-275.
- [14] Yeon Sil Kim.: Reirradiation of head and neck cancer in the era of intensity-modulated radiotherapy: patient selection, practical aspects, and current evidence, Radiation Oncology Journal 2017; 35 (1): 1-15.
- [15] Nieder G.: Second re-irradiation- review: A delicate balance between safety and efficacy, Medica Physica 58 (2019), 155-158.
- [16] Oinam SA et al.: DVH analysis and comparison of different radiobiological models using in-house developed software. J. Med. Phys 36 (4), 2011, pp 220-229.
- [17] Sminia P. et al.: Re-irradiation of human spinal cord. Strahlenther. Onkol. 2002, 178 (8).
- [18] Stewart F. A.: Retreatment tolerance of normal tissues, chapter 21 in the book: Steel G.: Basic Clinical Radiobiology 3rd Edition, ARNOLD Publishers, London, 2006.
- [19] Schroder C. et al.: Re-irradiation in the thorax – An analysis of efficacy and safety based on accumulated EQD2 doses, Radiotherapy and Oncology, Volume 152, P 56-62, November 01, 2020.